News
Hosted on MSN23d
FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathyThe treatment was developed by Capsida Biotherapeutics and called CAP-002. DEE caused by STXBP1 mutations is estimated to affect up to one in 26,000 children globally. It is associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback